Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

PURPOSE. The aim of this study was to investigate whether progression‐free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. MATERIALS AND METHODS. Individual data were collected from 15 Cancer and Leukemia Group B (615 patients) and 2 North C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaofei, Wang, Xiaoyi, Hodgson, Lydia, George, Stephen L., Sargent, Daniel J., Foster, Nate R., Ganti, Apar Kishor, Stinchcombe, Thomas E., Crawford, Jeffrey, Kratzke, Robert, Adjei, Alex A., Kindler, Hedy L., Vokes, Everett E., Pang, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330706/
https://www.ncbi.nlm.nih.gov/pubmed/28188257
http://dx.doi.org/10.1634/theoncologist.2016-0121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330706/
https://www.ncbi.nlm.nih.gov/pubmed/28188257
http://dx.doi.org/10.1634/theoncologist.2016-0121

Ejemplares similares